|
EIF4A3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.98179999999493E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.82200000000177E-05 |
| Normal-vs-Stage2 |
1.92827999999645E-05 |
| Normal-vs-Stage3 |
3.61309999999948E-05 |
| Normal-vs-Stage4 |
3.50040000000051E-05 |
| Stage1-vs-Stage2 |
1.027610E-01 |
| Stage1-vs-Stage3 |
4.692200E-01 |
| Stage1-vs-Stage4 |
3.002400E-01 |
| Stage2-vs-Stage3 |
3.043400E-01 |
| Stage2-vs-Stage4 |
5.833800E-01 |
| Stage3-vs-Stage4 |
6.457000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.95270000000237E-05 |
| Normal-vs-AfricanAmerican |
8.629800E-04 |
| Normal-vs-Asian |
1.438810E-03 |
| Caucasian-vs-AfricanAmerican |
3.250600E-01 |
| Caucasian-vs-Asian |
9.482400E-01 |
| AfricanAmerican-vs-Asian |
3.820800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65510999999841E-05 |
| Normal-vs-Female |
1.500430000001E-05 |
| Male-vs-Female |
2.774800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.404200E-04 |
| Normal-vs-Age(41-60Yrs) |
1.75838999999511E-05 |
| Normal-vs-Age(61-80Yrs) |
1.4498000000529E-07 |
| Normal-vs-Age(81-100Yrs) |
2.928000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.944200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.925600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.678200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.928550E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.673600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.477580E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.341200E-01 |
| Classical-VS-Follicular |
5.59169999192477E-09 |
| Classical-VS-Other |
6.917600E-01 |
| Classical-VS-Normal |
5.225700E-04 |
| Tall-VS-Follicular |
1.140010E-03 |
| Tall-VS-Other |
7.668000E-01 |
| Tall-VS-Normal |
1.108360E-02 |
| Follicular-VS-Other |
2.191800E-01 |
| Follicular-VS-Normal |
9.94010429522518E-11 |
| Other-VS-Normal |
2.638800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.19650000030403E-07 |
| Normal-vs-N1 |
2.49129999996267E-06 |
| N0-vs-N1 |
3.060400E-01 |
|
|
